Abstract
Purpose:
To evaluate the efficacy and safety of stereotactic radiotherapy (IRay™, Oraya) combined with Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV) treatment.
Methods:
Interventional twelve-month Pilot Study. Ten eyes of 10 patients with AMD and PCV were included. The polypoidal complex should be no closer to the optic disk than 3 mm, BCVA between 25 and 75 ETDRS letters, and axial length between 20 mm and 26 mm. At baseline, all the eyes received an intravitreal injection of Ranibizumab, followed by a single dose of 16 Gy delivered on the macular area with the IRay™ System. During monthly follow-up visits, further Ranibizumab injections were given PRN. Primary Outcomes were BCVA and Central Retinal Thickness (CRT) changes. Secondary Outcomes were mean injection number and PCV changes by means of ICGA.
Results:
At month six, mean BCVA improved from 62.8±11.6 to 66.8±13.7 ETDRS letters. Mean CRT decreased from 358.3±88.3 µm to 195.5±56 µm. Mean additional intravitreal injections were 1.9. The PCV aneurysmal bulge component was obliterated in all cases when included in the irradiation spot. No local or systemic adverse events occurred.
Conclusions:
Our preliminary data on combined Ranibizumab and stereotactic X-ray therapy of PCV showed a mean BCVA improvement, a mean CRT decrease and aneurismal component closure. The latest results will being shown first at ARVO.
Keywords: 412 age-related macular degeneration •
671 radiation therapy •
688 retina